Incyte Corp- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Incyte Corp 公司

Incyte Corporation 是一家生物制药公司，专注于发现、开发和商业化治疗药物。该公司在两个治疗领域开展业务。一个治疗领域是血液学/肿瘤学，包括骨髓增生性肿瘤和移植物抗宿主病，以及实体瘤和血液系统恶性肿瘤。其另一个治疗领域是炎症和自身免疫，包括其皮肤病商业特许经营权。其血液学和肿瘤学特许经营权包括六种产品，即 JAKAFI (ruxolitinib)、MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab)、PEMAZYRE (pemigatinib)、ICLUSIG (ponatinib)、NIKTIMVO (axatilimab-csfr) 和 ZYNYZ (retifanlimab-dlwr)，以及众多临床开发项目。该公司的产品线还包括两种一流的 Mas 相关 G 蛋白偶联受体（MRGPRX2）小分子拮抗剂和口服 MRGPRX4 拮抗剂 INCB000547。

Incyte Corp简介



公司代码INCY

公司名称Incyte Corp

上市日期Dec 06, 1993

CEOMr. Bill Meury

员工数量2617

证券类型Ordinary Share

年结日Dec 06

公司地址1801 Augustine Cut-Off

城市WILMINGTON

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编19803

电话13024986700

网址https://www.incyte.com/

公司代码INCY

上市日期Dec 06, 1993

CEOMr. Bill Meury

Incyte Corp公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Herve Hoppenot

Director

1.62M

-3.14%

Mr. Julian C. Baker

Independent Chairman of the Board

278.77K

--

Mr. Paul J. Clancy

Independent Director

147.17K

+0.19%

Mr. Jean-Jacques Bienaime ,

Independent Director

144.77K

+1.77%

Mr. Michael James Morrissey

Executive Vice President, Head - Global Technical Operations

86.16K

+5.70%

Dr. Katherine A. High, M.D.

Independent Director

66.08K

+3.96%

Dr. Otis W. Brawley, M.D.

Independent Director

50.10K

+5.29%

Dr. Susanne Schaffert, Ph.D.

Independent Director

37.95K

+4.60%

Dr. Pablo J. Cagnoni

President - Research and Development

35.48K

+62.39%

Mr. Lee Heeson

Executive Vice President - Incyte, International

32.31K

-1.41%

名称

名称/职务

职务

持股

持股变动

Mr. Herve Hoppenot

Director

1.62M

-3.14%

Mr. Julian C. Baker

Independent Chairman of the Board

278.77K

--

Mr. Paul J. Clancy

Independent Director

147.17K

+0.19%

Mr. Jean-Jacques Bienaime ,

Independent Director

144.77K

+1.77%

Mr. Michael James Morrissey

Executive Vice President, Head - Global Technical Operations

86.16K

+5.70%

Dr. Katherine A. High, M.D.

Independent Director

66.08K

+3.96%

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

JAKAFI revenues

763.79M

62.84%

OPZELURA revenues

164.50M

13.53%

JAKAVI product royalty revenues

109.71M

9.03%

NIKTIMVO revenues

36.15M

2.97%

OLUMIANT product royalty revenues

33.48M

2.75%

其他

107.89M

8.88%

暂无数据

业务

地区

业务USD

名称

营收

占比

JAKAFI revenues

763.79M

62.84%

OPZELURA revenues

164.50M

13.53%

JAKAVI product royalty revenues

109.71M

9.03%

NIKTIMVO revenues

36.15M

2.97%

OLUMIANT product royalty revenues

33.48M

2.75%

其他

107.89M

8.88%

股东统计

更新时间: 10月22日周三

持股股东

股东类型

持股股东

占比

Baker Bros. Advisors LP

15.66%

The Vanguard Group, Inc.

10.21%

Dodge & Cox

7.43%

BlackRock Institutional Trust Company, N.A.

5.95%

State Street Investment Management (US)

5.03%

其他

55.71%

持股股东

占比

Baker Bros. Advisors LP

15.66%

The Vanguard Group, Inc.

10.21%

Dodge & Cox

7.43%

BlackRock Institutional Trust Company, N.A.

5.95%

State Street Investment Management (US)

5.03%

其他

55.71%

股东类型

持股股东

占比

Investment Advisor/Hedge Fund

38.63%

Investment Advisor

37.21%

Hedge Fund

20.76%

Pension Fund

2.95%

Individual Investor

2.17%

Research Firm

2.06%

Bank and Trust

1.47%

Sovereign Wealth Fund

0.77%

Family Office

0.29%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

1419

203.92M

103.87%

-180.79K

2025Q2

1423

201.60M

103.23%

-197.50K

2025Q1

1457

199.01M

102.81%

-12.15M

2024Q4

1448

191.80M

99.11%

-19.23M

2024Q3

1401

192.85M

100.02%

-35.92M

2024Q2

1385

209.06M

108.78%

-39.98M

2024Q1

1357

227.85M

101.54%

-21.15M

2023Q4

1323

228.89M

102.19%

-14.49M

2023Q3

1300

224.25M

100.13%

-17.63M

2023Q2

1306

220.30M

98.76%

-17.67M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Baker Bros. Advisors LP

30.74M

15.74%

+256.17K

+0.84%

Jun 30, 2025

The Vanguard Group, Inc.

20.05M

10.27%

+134.71K

+0.68%

Jun 30, 2025

Dodge & Cox

14.60M

7.47%

-269.15K

-1.81%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

11.69M

5.99%

-228.50K

-1.92%

Jun 30, 2025

State Street Investment Management (US)

9.88M

5.06%

-159.70K

-1.59%

Jun 30, 2025

AQR Capital Management, LLC

8.20M

4.2%

+1.47M

+21.75%

Jun 30, 2025

Geode Capital Management, L.L.C.

4.35M

2.23%

+139.74K

+3.32%

Jun 30, 2025

Renaissance Technologies LLC

3.88M

1.99%

+173.20K

+4.67%

Jun 30, 2025

LSV Asset Management

3.86M

1.98%

+223.86K

+6.15%

Jun 30, 2025

Invesco Capital Management LLC

2.96M

1.52%

+218.65K

+7.97%

Jun 30, 2025

持股ETF



更新时间: 10月6日周一

机构名称

占比

iShares Genomics Immunology and Healthcare ETF

4.92%

First Trust NYSE Arca Biotechnology Index Fund

4%

Invesco Biotechnology & Genome ETF

3.34%

SPDR S&P Biotech ETF

2.86%

VanEck Biotech ETF

2.39%

Bushido Capital US Equity ETF

2.34%

Strategas Global Policy Opportunities ETF

2.31%

Innovator IBD Breakout Opportunities ETF

2.2%

Virtus LifeSci Biotech Products ETF

2.04%

Invesco S&P 500 Equal Weight Health Care ETF

2.02%

iShares Genomics Immunology and Healthcare ETF

占比4.92%

First Trust NYSE Arca Biotechnology Index Fund

占比4%

Invesco Biotechnology & Genome ETF

占比3.34%

SPDR S&P Biotech ETF

占比2.86%

VanEck Biotech ETF

占比2.39%

Bushido Capital US Equity ETF

占比2.34%

Strategas Global Policy Opportunities ETF

占比2.31%

Innovator IBD Breakout Opportunities ETF

占比2.2%

Virtus LifeSci Biotech Products ETF

占比2.04%

Invesco S&P 500 Equal Weight Health Care ETF

占比2.02%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据